Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gender Discrimination Suits: Cases Against Pharma Continue Even As Payouts Slow

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis will pay $8m to settle second case; last year Daiichi Sankyo settled gender discrimination class action for the same amount and action against Bayer was dismissed following confidential resolution. Cases are ongoing against Merck and Forest.

Advertisement

Related Content

Merck Gender Discrimination Class Action Alleges Maternity Leave Leads To Manager Pay Cuts
Forest Gender Discrimination Suit Cites “Striking” Similarities With Other Firms
Supreme Court's Wal-Mart Ruling Could Curtail Pharma Gender Discrimination Cases
Bayer Gender Discrimination Suit Cites Internal Articles, Bidding Process For Advancement
Novartis Will Track Gender Disparities In Performance Evaluations Under Settlement
Sales Reps Prove Compelling Plaintiffs As Novartis Loses Jury Trial Gamble In Gender Discrimination Case; Pay Policy Could Change Industry-wide

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS078998

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel